Levofolic

Levoleucovorin disodium, the active ingredient in Levofolic, is a folate analog presented as a sterile intravenous solution for injection use. It provides a reduced form of folic acid that helps mitigate the toxicity of antifolate chemotherapy agents such as methotrexate in patients receiving high‑dose regimens.

GNH USA supplies Levofolic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Levofolic is used as a rescue agent in clinical situations involving antifolate chemotherapy. - Methotrexate toxicity: Reduces toxic effects associated with methotrexate therapy. - High‑dose methotrexate rescue: Restores folate pools after high‑dose methotrexate administration. - Chemotherapy supportive care: Supports patients receiving antifolate‑based chemotherapy regimens.

Levofolic may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis after infusion. - Diarrhea: loose stools occurring within 24 hours. - Fever: transient low‑grade temperature rise. - Headache: mild cranial discomfort. - Injection site pain: local discomfort at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Acute renal failure: sudden loss of kidney function. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Severe neutropenia: marked reduction in white blood cells. - Thromboembolic events: rare clot formation. - Hypersensitivity syndrome: multi‑system allergic response.

Before using Levofolic, clinicians should consider several safety measures. - Renal function: assess creatinine clearance and adjust use in renal impairment. - Hepatic function: evaluate liver enzymes, especially in patients with pre‑existing liver disease. - Pregnancy status: avoid use unless benefits outweigh potential risks. - Concomitant antifolates: monitor closely when other folate pathway agents are co‑administered. - Electrolyte balance: correct significant abnormalities prior to infusion. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levofolic can interact with other medicines that affect folate metabolism or renal clearance.

Major Interactions (Avoid): - High‑dose methotrexate: concurrent use without proper timing may reduce rescue effectiveness. - Nephrotoxic agents (e.g., cisplatin): combined renal stress can increase toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may impair renal excretion of levoleucovorin. - Proton pump inhibitors: potential alteration of folate absorption (though less relevant for IV). - Sulfonamides: competitive inhibition of folate pathways. - Anticonvulsants (e.g., phenytoin): may increase folate turnover. - Diuretics: affect fluid balance during infusion.